HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A proteolytic cascade controls lysosome rupture and necrotic cell death mediated by lysosome-destabilizing adjuvants.

Abstract
Recent studies have linked necrotic cell death and proteolysis of inflammatory proteins to the adaptive immune response mediated by the lysosome-destabilizing adjuvants, alum and Leu-Leu-OMe (LLOMe). However, the mechanism by which lysosome-destabilizing agents trigger necrosis and proteolysis of inflammatory proteins is poorly understood. The proteasome is a cellular complex that has been shown to regulate both necrotic cell death and proteolysis of inflammatory proteins. We found that the peptide aldehyde proteasome inhibitors, MG115 and MG132, block lysosome rupture, degradation of inflammatory proteins and necrotic cell death mediated by the lysosome-destabilizing peptide LLOMe. However, non-aldehyde proteasome inhibitors failed to prevent LLOMe-induced cell death suggesting that aldehyde proteasome inhibitors triggered a pleotropic effect. We have previously shown that cathepsin C controls lysosome rupture, necrotic cell death and the adaptive immune response mediated by LLOMe. Using recombinant cathepsin C, we found that aldehyde proteasome inhibitors directly block cathepsin C, which presumably prevents LLOMe toxicity. The cathepsin B inhibitor CA-074-Me also blocks lysosome rupture and necrotic cell death mediated by a wide range of necrosis inducers, including LLOMe. Using cathepsin-deficient cells and recombinant cathepsins, we demonstrate that the cathepsins B and C are not required for the CA-074-Me block of necrotic cell death. Taken together, our findings demonstrate that lysosome-destabilizing adjuvants trigger an early proteolytic cascade, involving cathepsin C and a CA-074-Me-dependent protease. Identification of these early events leading to lysosome rupture will be crucial in our understanding of processes controlling necrotic cell death and immune responses mediated by lysosome-destabilizing adjuvants.
AuthorsJürgen Brojatsch, Heriberto Lima, Alak K Kar, Lee S Jacobson, Stefan M Muehlbauer, Kartik Chandran, Felipe Diaz-Griffero
JournalPloS one (PLoS One) Vol. 9 Issue 6 Pg. e95032 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID24893007 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Pharmaceutic
  • Aldehydes
  • Antigens, Bacterial
  • Bacterial Toxins
  • Dipeptides
  • Leupeptins
  • Peptides
  • Proteasome Inhibitors
  • anthrax toxin
  • carbobenzoxy-leucyl-leucyl-norvalinal
  • leucyl-leucine-methyl ester
  • N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline
  • Cathepsin C
  • Cathepsin B
Topics
  • Adjuvants, Pharmaceutic (pharmacology)
  • Aldehydes (pharmacology)
  • Animals
  • Antigens, Bacterial (pharmacology)
  • Bacterial Toxins (pharmacology)
  • Cathepsin B (antagonists & inhibitors, metabolism)
  • Cathepsin C (antagonists & inhibitors, metabolism)
  • Dipeptides (pharmacology)
  • Inflammation (metabolism, pathology)
  • Leupeptins (pharmacology)
  • Lysosomes (drug effects, metabolism, ultrastructure)
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Necrosis
  • Peptides (pharmacology)
  • Proteasome Inhibitors (pharmacology)
  • Proteolysis (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: